402 related articles for article (PubMed ID: 34661964)
1. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
[TBL] [Abstract][Full Text] [Related]
2. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya.
Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P
AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533
[TBL] [Abstract][Full Text] [Related]
3. Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.
Stone J; Trickey A; Walker JG; Bivegete S; Semchuk N; Sazonova Y; Varetska O; Altice FL; Saliuk T; Vickerman P
J Int AIDS Soc; 2023 Apr; 26(4):e26073. PubMed ID: 37012669
[TBL] [Abstract][Full Text] [Related]
4. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
[TBL] [Abstract][Full Text] [Related]
5. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
[TBL] [Abstract][Full Text] [Related]
7. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
[TBL] [Abstract][Full Text] [Related]
8. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
9. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
[TBL] [Abstract][Full Text] [Related]
10. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania.
Kawambwa RH; Majigo MV; Mohamed AA; Matee MI
BMC Public Health; 2020 Feb; 20(1):177. PubMed ID: 32019536
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors associated with HIV-1 infection among people who inject drugs in Dar es Salaam, Tanzania: a sign of successful intervention?
Likindikoki SL; Mmbaga EJ; Leyna GH; Moen K; Makyao N; Mizinduko M; Mwijage AI; Faini D; Leshabari MT; Meyrowitsch DW
Harm Reduct J; 2020 Mar; 17(1):18. PubMed ID: 32209110
[TBL] [Abstract][Full Text] [Related]
14. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
Stone J; Fraser H; Young AM; Havens JR; Vickerman P
Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study.
Cepeda JA; Eritsyan K; Vickerman P; Lyubimova A; Shegay M; Odinokova V; Beletsky L; Borquez A; Hickman M; Beyrer C; Martin NK
Lancet HIV; 2018 Oct; 5(10):e578-e587. PubMed ID: 30033374
[TBL] [Abstract][Full Text] [Related]
16. The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
Mohamed Z; Rwegasha J; Kim JU; Shimakawa Y; Poiteau L; Chevaliez S; Bhagani S; Taylor-Robinson SD; Thursz MR; Mbwambo J; Lemoine M
J Viral Hepat; 2018 Dec; 25(12):1438-1445. PubMed ID: 29974582
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.
Lambdin BH; Lorvick J; Mbwambo JK; Rwegasha J; Hassan S; Lum P; Kral AH
Int J Drug Policy; 2017 Jul; 45():64-69. PubMed ID: 28628854
[TBL] [Abstract][Full Text] [Related]
18. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
19. HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination.
Leyna GH; Makyao N; Mwijage A; Ramadhan A; Likindikoki S; Mizinduko M; Leshabari MT; Moen K; Mmbaga EJ
Harm Reduct J; 2019 Dec; 16(1):68. PubMed ID: 31829199
[TBL] [Abstract][Full Text] [Related]
20. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020).
Palmateer N; Hamill V; Bergenstrom A; Bloomfield H; Gordon L; Stone J; Fraser H; Seyler T; Duan Y; Tran R; Trayner K; Biggam C; Smith S; Vickerman P; Hickman M; Hutchinson S
Int J Drug Policy; 2022 Nov; 109():103872. PubMed ID: 36202039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
